Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer : outcomes and biomarker analysis from the SUMMIT trial
Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved..
BACKGROUND: HER2 mutations are targetable alterations in patients with hormone receptor-positive (HR+) metastatic breast cancer (MBC). In the SUMMIT basket study, patients with HER2-mutant MBC received neratinib monotherapy, neratinib + fulvestrant, or neratinib + fulvestrant + trastuzumab (N + F + T). We report results from 71 patients with HR+, HER2-mutant MBC, including 21 (seven in each arm) from a randomized substudy of fulvestrant versus fulvestrant + trastuzumab (F + T) versus N + F + T.
PATIENTS AND METHODS: Patients with HR+ HER2-negative MBC with activating HER2 mutation(s) and prior cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) therapy received N + F + T (oral neratinib 240 mg/day with loperamide prophylaxis, intramuscular fulvestrant 500 mg on days 1, 15, and 29 of cycle 1 then q4w, intravenous trastuzumab 8 mg/kg then 6 mg/kg q3w) or F + T or fulvestrant alone. Those whose disease progressed on F + T or fulvestrant could cross-over to N + F + T. Efficacy endpoints included investigator-assessed objective response rate (ORR), clinical benefit rate (RECIST v1.1), duration of response, and progression-free survival (PFS). Plasma and/or formalin-fixed paraffin-embedded tissue samples were collected at baseline; plasma was collected during and at end of treatment. Extracted DNA was analyzed by next-generation sequencing.
RESULTS: ORR for 57 N + F + T-treated patients was 39% [95% confidence interval (CI) 26% to 52%); median PFS was 8.3 months (95% CI 6.0-15.1 months). No responses occurred in fulvestrant- or F + T-treated patients; responses in patients crossing over to N + F + T supported the requirement for neratinib in the triplet. Responses were observed in patients with ductal and lobular histology, 1 or ≥1 HER2 mutations, and co-occurring HER3 mutations. Longitudinal circulating tumor DNA sequencing revealed acquisition of additional HER2 alterations, and mutations in genes including PIK3CA, enabling further precision targeting and possible re-response.
CONCLUSIONS: The benefit of N + F + T for HR+ HER2-mutant MBC after progression on CDK4/6is is clinically meaningful and, based on this study, N + F + T has been included in the National Comprehensive Cancer Network treatment guidelines. SUMMIT has improved our understanding of the translational implications of targeting HER2 mutations with neratinib-based therapy.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:34 |
|---|---|
| Enthalten in: |
Annals of oncology : official journal of the European Society for Medical Oncology - 34(2023), 10 vom: 18. Okt., Seite 885-898 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Jhaveri, K [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 09.11.2023 Date Revised 19.11.2023 published: Print-Electronic ClinicalTrials.gov: NCT01953926, NCT01670877, NCT03734029, NCT04639219, NCT05372614 Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.annonc.2023.08.003 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM360963420 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM360963420 | ||
| 003 | DE-627 | ||
| 005 | 20231226084136.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.annonc.2023.08.003 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1203.xml |
| 035 | |a (DE-627)NLM360963420 | ||
| 035 | |a (NLM)37597578 | ||
| 035 | |a (PII)S0923-7534(23)00800-1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Jhaveri, K |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer |b outcomes and biomarker analysis from the SUMMIT trial |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 09.11.2023 | ||
| 500 | |a Date Revised 19.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT01953926, NCT01670877, NCT03734029, NCT04639219, NCT05372614 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved. | ||
| 520 | |a BACKGROUND: HER2 mutations are targetable alterations in patients with hormone receptor-positive (HR+) metastatic breast cancer (MBC). In the SUMMIT basket study, patients with HER2-mutant MBC received neratinib monotherapy, neratinib + fulvestrant, or neratinib + fulvestrant + trastuzumab (N + F + T). We report results from 71 patients with HR+, HER2-mutant MBC, including 21 (seven in each arm) from a randomized substudy of fulvestrant versus fulvestrant + trastuzumab (F + T) versus N + F + T | ||
| 520 | |a PATIENTS AND METHODS: Patients with HR+ HER2-negative MBC with activating HER2 mutation(s) and prior cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) therapy received N + F + T (oral neratinib 240 mg/day with loperamide prophylaxis, intramuscular fulvestrant 500 mg on days 1, 15, and 29 of cycle 1 then q4w, intravenous trastuzumab 8 mg/kg then 6 mg/kg q3w) or F + T or fulvestrant alone. Those whose disease progressed on F + T or fulvestrant could cross-over to N + F + T. Efficacy endpoints included investigator-assessed objective response rate (ORR), clinical benefit rate (RECIST v1.1), duration of response, and progression-free survival (PFS). Plasma and/or formalin-fixed paraffin-embedded tissue samples were collected at baseline; plasma was collected during and at end of treatment. Extracted DNA was analyzed by next-generation sequencing | ||
| 520 | |a RESULTS: ORR for 57 N + F + T-treated patients was 39% [95% confidence interval (CI) 26% to 52%); median PFS was 8.3 months (95% CI 6.0-15.1 months). No responses occurred in fulvestrant- or F + T-treated patients; responses in patients crossing over to N + F + T supported the requirement for neratinib in the triplet. Responses were observed in patients with ductal and lobular histology, 1 or ≥1 HER2 mutations, and co-occurring HER3 mutations. Longitudinal circulating tumor DNA sequencing revealed acquisition of additional HER2 alterations, and mutations in genes including PIK3CA, enabling further precision targeting and possible re-response | ||
| 520 | |a CONCLUSIONS: The benefit of N + F + T for HR+ HER2-mutant MBC after progression on CDK4/6is is clinically meaningful and, based on this study, N + F + T has been included in the National Comprehensive Cancer Network treatment guidelines. SUMMIT has improved our understanding of the translational implications of targeting HER2 mutations with neratinib-based therapy | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a ERBB2 | |
| 650 | 4 | |a HER2-mutant | |
| 650 | 4 | |a hormone receptor-positive | |
| 650 | 4 | |a metastatic breast cancer | |
| 650 | 4 | |a neratinib | |
| 650 | 7 | |a Fulvestrant |2 NLM | |
| 650 | 7 | |a 22X328QOC4 |2 NLM | |
| 650 | 7 | |a neratinib |2 NLM | |
| 650 | 7 | |a JJH94R3PWB |2 NLM | |
| 650 | 7 | |a Receptor, ErbB-2 |2 NLM | |
| 650 | 7 | |a EC 2.7.10.1 |2 NLM | |
| 650 | 7 | |a Trastuzumab |2 NLM | |
| 650 | 7 | |a P188ANX8CK |2 NLM | |
| 700 | 1 | |a Eli, L D |e verfasserin |4 aut | |
| 700 | 1 | |a Wildiers, H |e verfasserin |4 aut | |
| 700 | 1 | |a Hurvitz, S A |e verfasserin |4 aut | |
| 700 | 1 | |a Guerrero-Zotano, A |e verfasserin |4 aut | |
| 700 | 1 | |a Unni, N |e verfasserin |4 aut | |
| 700 | 1 | |a Brufsky, A |e verfasserin |4 aut | |
| 700 | 1 | |a Park, H |e verfasserin |4 aut | |
| 700 | 1 | |a Waisman, J |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, E S |e verfasserin |4 aut | |
| 700 | 1 | |a Spanggaard, I |e verfasserin |4 aut | |
| 700 | 1 | |a Reid, S |e verfasserin |4 aut | |
| 700 | 1 | |a Burkard, M E |e verfasserin |4 aut | |
| 700 | 1 | |a Vinayak, S |e verfasserin |4 aut | |
| 700 | 1 | |a Prat, A |e verfasserin |4 aut | |
| 700 | 1 | |a Arnedos, M |e verfasserin |4 aut | |
| 700 | 1 | |a Bidard, F-C |e verfasserin |4 aut | |
| 700 | 1 | |a Loi, S |e verfasserin |4 aut | |
| 700 | 1 | |a Crown, J |e verfasserin |4 aut | |
| 700 | 1 | |a Bhave, M |e verfasserin |4 aut | |
| 700 | 1 | |a Piha-Paul, S A |e verfasserin |4 aut | |
| 700 | 1 | |a Suga, J M |e verfasserin |4 aut | |
| 700 | 1 | |a Chia, S |e verfasserin |4 aut | |
| 700 | 1 | |a Saura, C |e verfasserin |4 aut | |
| 700 | 1 | |a Garcia-Saenz, J Á |e verfasserin |4 aut | |
| 700 | 1 | |a Gambardella, V |e verfasserin |4 aut | |
| 700 | 1 | |a de Miguel, M J |e verfasserin |4 aut | |
| 700 | 1 | |a Gal-Yam, E N |e verfasserin |4 aut | |
| 700 | 1 | |a Rapael, A |e verfasserin |4 aut | |
| 700 | 1 | |a Stemmer, S M |e verfasserin |4 aut | |
| 700 | 1 | |a Ma, C |e verfasserin |4 aut | |
| 700 | 1 | |a Hanker, A B |e verfasserin |4 aut | |
| 700 | 1 | |a Ye, D |e verfasserin |4 aut | |
| 700 | 1 | |a Goldman, J W |e verfasserin |4 aut | |
| 700 | 1 | |a Bose, R |e verfasserin |4 aut | |
| 700 | 1 | |a Peterson, L |e verfasserin |4 aut | |
| 700 | 1 | |a Bell, J S K |e verfasserin |4 aut | |
| 700 | 1 | |a Frazier, A |e verfasserin |4 aut | |
| 700 | 1 | |a DiPrimeo, D |e verfasserin |4 aut | |
| 700 | 1 | |a Wong, A |e verfasserin |4 aut | |
| 700 | 1 | |a Arteaga, C L |e verfasserin |4 aut | |
| 700 | 1 | |a Solit, D B |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Annals of oncology : official journal of the European Society for Medical Oncology |d 1990 |g 34(2023), 10 vom: 18. Okt., Seite 885-898 |w (DE-627)NLM012606308 |x 1569-8041 |7 nnns |
| 773 | 1 | 8 | |g volume:34 |g year:2023 |g number:10 |g day:18 |g month:10 |g pages:885-898 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.annonc.2023.08.003 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 34 |j 2023 |e 10 |b 18 |c 10 |h 885-898 | ||